 Home > Active Ingredient News > Antitumor Therapy > ASCO 2021: Summary Overview and Outlook 2

ASCO 2021: Summary Overview and Outlook 2

 Last Update: 2021-06-10
 Source: Internet
 Author: User

Tags

1 4 teaspoon

5 radical 2

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

ASCO 2021: Summary Overview and Outlook 1

For followers of the academic progress of oncology, the release of the Asco summary is one of the biggest events of the year.

The latest abstract will be released on June 3 at 5 pm Eastern Time (the day before the conference).

Excerpts from important Asco latest abstracts

Highlights of Asco's latest summary results preview excerpt 1:

Highlights of Asco's latest summary results preview excerpt 1: Highlights of Asco's latest summary results preview excerpt 1:

AstraZeneca/Merck & Co Lynparza Olympia (Merck & Co Lynparza Olympia): PH (3) after adjuvant chemotherapy, Lynparza in germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer after (neo) adjuvant chemotherapy test
Merck Keynote-564: Keytruda as an adjuvant treatment of renal cell carcinoma after nephrectomy ph3 test
Novartis 177Lu-PSMA-617: Phase 3 clinical trial of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer
Junshi Biosciences and Coherus Biosciences Jupiter-02: Toripalimab combined with chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma ph3 trial
BMS Opdivo and Yervoy Checkmate-648: Opdivo plus Yervoy and other chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma The first result of CheckMate 648 study.

2536 4 SD in 10 evaluable pts Sutro STRO-002 FRα inhibitor 5550 Of 31 evaluable, 1 CR, 4 confirmed PR, and 5 unconfirmed PR.

2536 4 SD in 10 evaluable pts Sutro STRO-002 FRα inhibitor 5550 Of 31 evaluable, 1 CR, 4 confirmed PR, and 5 unconfirmed PR.

2536 4 SD in 10 evaluable pts SQZ BiotechnologiesSQZ-PBMC-HPV-101
T-cell surface glycoprotein CD8 stimulant

T-cell surface glycoprotein CD8 stimulant
25364 SD in 10 evaluable pts Sutro STRO-002 FRα inhibitor 5550 Of 31 evaluable, 1 CR, 4 confirmed PR, and 5 unconfirmed PR.

Of course, this is far from a detailed introduction of important oral speeches, and more data will be released in the next few weeks, so please stay tuned! Of course, this is far from a detailed introduction of important oral speeches, and more data will be released in the next few weeks, so please stay tuned!
For more content, follow the ASCO special page of Metz Medical: https://meeting.

Reference source: https://meetinglibrary.

https://meetinglibrary.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.